Tofacitinib combined with local low-dose ixekizumab injection benefits those with peripheral psoriatic arthritis  

作　　者：Yours Sincerely Ruiyuan Xia Weixin Zhang Jing Hang Zhiqiang Yin 

机构地区：[1]Department of Dermatology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China [2]Department of Ultrasound,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China.

出　　处：《The Journal of Biomedical Research》2024年第1期92-94,共3页生物医学研究杂志（英文版）

基　　金：supported by the National Natural Science Foundation of China(Grant No.82073439).

摘　　要：Dear Editor,Treating psoriatic arthritis(PsA)is always difficult.Systemic treatments can be administered either orally or through intramuscular and intra-articular injection,including conventional synthetics,biologics and targeted synthetic disease-modifying antirheumatic drugs[1].The alternatives,topical external therapies,are not effective on joint lesions due to drug permeability issues.Drugs injected into the articular cavity are also unsuitable for small peripheral joint lesions,the most common manifestations of PsA.The limited treatment options for PsA present a challenge.

关 键 词：INJECTION DRUGS cavity treatment 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]